

## EXPORT-IMPORT BANK OF THE UNITED STATES

### Notice of Open Special Meeting of the Advisory Committee of the Export-Import Bank of the United States (Export-Import Bank).

**SUMMARY:** The Advisory Committee was established by Public Law 98-181, November 30, 1983, to advise the Export-Import Bank on its programs and to provide comments for inclusion in the reports of the Export-Import Bank of the United States to Congress.

**Time and Place:** Wednesday, September 20, 2000, at 9:30 AM to 12:30 PM. The meeting will be held at the Export-Import Bank in Room 1143, 811 Vermont Avenue, NW, Washington, DC 20571.

**Agenda:** This meeting will include a follow-up discussion of the Institute of International Economics study titled "The Future of the U.S. Ex-Im Bank", and a discussion of Ex-Im Bank's e-commerce initiatives, and other matters.

**Public Participation:** The meeting will be open to public participation, and the last 10 minutes will be set aside for oral questions or comments. Members of the public may also file written statement(s) before or after the meeting. If any person wishes auxiliary aids (such as a sign language interpreter) or other special accommodations, please contact, prior to September 13, 2000, Teri Stumpf, Room 1215, 811 Vermont Avenue, NW, Washington, DC 20571, Voice: (202) 565-3502 or TDD (202) 565-3377.

**FOR FURTHER INFORMATION CONTACT:** For further information, contact Teri Stumpf, Room 1215, 811 Vermont Ave., NW, Washington, DC 20571, (202) 565-3502.

John M. Niehuss,  
General Counsel.

[FR Doc. 00-23165 Filed 9-8-00; 8:45 am]

BILLING CODE 6690-01-M

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies

owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 5, 2000.

**A. Federal Reserve Bank of Chicago** (Phillip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. *Wintrust Financial Corporation*, Lake Forest, Illinois; to acquire 100 percent of the voting shares of Northbrook Bank and Trust Company (in formation), Northbrook, Illinois.

Board of Governors of the Federal Reserve System, September 5, 2000.

**Robert deV. Frierson,**

*Associate Secretary of the Board.*

[FR Doc. 00-23159 Filed 9-8-00; 8:45 am]

BILLING CODE 6210-01-P

## FEDERAL RESERVE SYSTEM

### Federal Open Market Committee; Domestic Policy Directive of June 27 and 28, 2000

In accordance with § 71.5 of its rules regarding availability of information (12 CFR part 271), there is set forth below the domestic policy directive issued by the Federal Open Market Committee at its meeting held on June 27 and 28, 2000.<sup>1</sup>

The Federal Open Market Committee seeks monetary and financial conditions

that will foster price stability and promote sustainable growth in output. To further its long-run objectives, the Committee in the immediate future seeks conditions in reserve markets consistent with maintaining the federal funds rate at an average of around 6½ percent.

By order of the Federal Open Market Committee, September 5, 2000.

**Donald L. Kohn,**

*Secretary, Federal Open Market Committee.*

[FR Doc. 00-23213 Filed 9-8-00; 8:45 am]

BILLING CODE 6210-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

### Findings of Scientific Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case:

*William A. Simmons, Ph.D., University of Texas Southwestern Medical Center:* Based on the report of an investigation conducted by the University of Texas Southwestern Medical Center (UTSW) and additional analysis conducted by ORI in its oversight review, the U.S. Public Health Service (PHS) finds that Dr. Simmons engaged in scientific misconduct by falsifying research supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) grant R01 DK47692, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, grants R01 AR38319 and P01 AR09989, National Institute of Allergy and Infectious Diseases (NIAID), NIH, grant R01 AI42860, and National Cancer Institute (NCI), NIH, grant T32 CA09082.

Specifically, while a graduate student and postdoctoral fellow at UTSW, Dr. Simmons manipulated results of cytotoxic T-lymphocyte (CTL) assays by adding predetermined amounts of radioactivity to scintillation counting vials rather than carrying out the assays as claimed.

As a result of falsifying these assays over a minimum of five years, none of Dr. Simmons research can be considered reliable and the publications identified below have been, or soon will be, retracted or corrected. The falsified research also was reported in the 1 R01 AI42860-01 grant application, "A new

<sup>1</sup> Copies of the Minutes of the Federal Open Market Committee meeting of June 27 and 28, 2000, which include the domestic policy directive issued at that meeting, are available upon request to the Board of Governors of the Federal Reserve System, Washington, DC 20551. The minutes are published in the Federal Reserve Bulletin and in the Board's annual report.

MHC locus influencing class I peptide display." Additionally, Dr. Simmons was responsible for falsifying Figure 3 published in *J. Immunol.* 159:2750–2759, 1997, by substituting preparations of chemically synthesized oligopeptide for natural peptides obtained from T cells isolated from B27 transgenic rats. These actions adversely and materially affected the laboratory's ongoing research into the role that human histocompatibility leukocyte antigens play in the development of disease.

The publications affected are:

- Simmons, W.A., Summerfield, S.G., Roopenian, D.C., Slaughter, C.A., Suberi, A.R., Gaskell, S.J., Bordoli, R.S., Hoyes, J., Moomaw, C.R., Colbert, R.A., Leong, L.Y., Butcher, C.W., Hammer, R.E., & Taurog, J.D. "Novel HY peptide antigens presented by HLA-B27." *J. Immunol.* 159:2750–2759, 1997 (being retracted).

- Simmons, W.A., Leong, L.Y., Satumtira, N., Butcher, G.W., Howard, J.C., Richardson, J.A., Slaughter, C.A., Hammer, R.F., & Taurog, J.D. "Rat MHC-linked peptide transporter alleles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease." *J. Immunol.* 156:1661–1667, 1996 (being retracted).

- Simmons, W.A., Roopenian, D.C., Summerfield, S.G., Jones, R.C., Galocha, B., Christianson, G.J., Maika, S.D., Zhou, M., Gaskell, S.J., Bordoli, R.S., Ploegh, H.L., Slaughter, C.A., Lindahl, K.F., Hammer, R.E., & Taurog, J.D. "A new MHC locus that influences class I peptide presentation." *Immunity* 7:641–651, 1997 (retracted).

- Simmons, W.A., Taurog, J.D., Hammer, R.E., & Breban, M. "Sharing of an HLA-B27-restricted H-Y antigen between rat and mouse." *Immunogenetics* 38:351–358, 1993 (retracted).

- Zhou, M., Sayad, A., Simmons, W.A., Jones, R.C., Maika, S.D., Satumtira, N., Dorris, M.L., Gaskell, S.J., Bordoli, R.S., Sartor, R.B., Slaughter, C.A., Richardson, J.A., Hammer, R.F., & Taurog, J.D. "The specificity of peptides bound to human histocompatibility leukocyte antigen (HLA)-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats." *J. Exp. Med.* 188:877–886, 1998 (published erratum).

Dr. Simmons has accepted the PHS findings and has entered into a Voluntary Exclusion Agreement with PHS in which he has voluntarily agreed for a period of five (5) years, beginning on August 22, 2000:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g.,

grants and cooperative agreements) of the United States Government as defined in 45 C.F.R. Part 76 (Debarment Regulations);

(2) to exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

#### FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative Oversight, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

**Chris Pascal,**

*Director, Office of Research Integrity.*

[FR Doc. 00–23215 Filed 9–8–00; 8:45 am]

BILLING CODE 4160–17–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Healthcare Research and Quality

#### Contract Review Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act as amended (5 U.S.C., Appendix 2), announcement is made of an Agency for Healthcare Research and Quality (AHRQ) Technical Review Committee (TRC) meeting. This TRC's charge is to provide review of contract proposals and recommendations to the Director, AHRQ, regarding the technical merit of proposals submitted in response to a Request for Proposals (RFPs) regarding "Developing Tools to Enhance Quality and Patient Safety Through Informatics". The RFP was published in the Commerce Business Daily on June 29, 2000.

The upcoming TRC meeting will be closed to the public in accordance with the Federal Advisory Committee Act (FACA), section 10(d) of 5 U.S.C., Appendix 2, implementing regulations, and procurement regulations, 41 CFR 101–6.1023 and 48 CFR section 315.604(d). The discussions at this meeting of contract proposals submitted in response to the above-referenced RFP are likely to reveal proprietary information and personal information concerning individuals associated with the proposals. Such information is exempt from disclosure under the above-cited FACA provision that protects the free exchange of candid views, and under the procurement rules that prevent undue interference with Committee and Department operations.

*Name of TRC:* The Agency for Healthcare Research and Quality—"Developing Tools to Enhance Quality

and Patient Safety Through Informatics".

*Date:* September 11, 2000 (Closed to the public).

*Place:* Gaithersburg Residence Inn, 9721 Washington Blvd., Gaithersburg Maryland, 20878.

*Contact Person:* Anyone wishing to obtain information regarding this meeting should contact Bonnie Campbell, Office of Research Review, Education, and Policy, Agency for Healthcare Research and Quality, 2101 East Jefferson Street, Suite 400, Rockville, Maryland, 20852, 301–594–1846.

This notice is being published less than 15 days prior to the September 11th meeting due to the time constraints of reviews and funding cycles.

Dated: September 1, 2000.

**John M. Eisenberg,**

*Director.*

[FR Doc. 00–23193 Filed 9–08–00; 8:45 am]

BILLING CODE 4160–90–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[30DAY–66–00]

#### Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–7090. Send written comments to CDC, Desk Officer; Human Resources and Housing Branch, New Executive Office Building, Room 10235; Washington, DC 20503. Written comments should be received within 30 days of this notice.

#### Proposed Project

Youth Risk Behavior Survey—(0920–0258)—New—National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). The proposed project is the 2001 national school-based Youth Risk Behavior Survey. The purpose of this request is to renew OMB clearance to continue an ongoing biennial survey among high school students attending regular public, private, and Catholic schools in grades 9–12. The survey assesses priority health risk behaviors related to the major preventable causes of mortality,